Prosecution Insights
Last updated: November 04, 2026
Application No. 19/031,506

ENDOVASCULAR MOBILE BALLOON SUPPORT CATHETER

Final Rejection §102§DOUBLEPATENT
Filed
Jan 18, 2025
Priority
Jun 17, 2015 — GR 20150100278 +4 more
Examiner
TANNER, JOCELIN C
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Shuttle Catheters Pc
OA Round
2 (Final)
72%
Grant Probability
Favorable
3-4
OA Rounds
1y 4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
774 granted / 1071 resolved
+2.3% vs TC avg
Strong +35% interview lift
Without
With
+34.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
33 currently pending
Career history
1112
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
48.7%
+8.7% vs TC avg
§102
22.0%
-18.0% vs TC avg
§112
22.2%
-17.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1071 resolved cases

Office Action

§102 §DOUBLEPATENT
DETAILED ACTION This Office Action is in response to the Amendment filed 25 August 2026. Claim(s) 9 is currently pending. The Examiner acknowledges cancelled claims 1-8. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Interpretation The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. No claim limitation has been interpreted under 35 U.S.C. 112(f) because each term (e.g., ‘elongated first ring’) connotes sufficient structure to a POSITA. See MPEP § 2181. If applicant contends otherwise, please point to supporting disclosure. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim 9 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 12,472,333. As shown in the mapping below, claim 1 of the reference patent includes all the limitations of claim 9 of the instant application, while also reciting further limitations, i.e. a second ring, elongated first ring. The term, elongated first ring, is an obvious variant of the patented claims and does not critically or functionally differentiate the capability or function of the surgical device. Every limitation in the application under examination claims is recited in the conflicting reference patent claims and the differences between the claims are highlighted below by bolding all limitations that differ, italicizing additional limitations and underlining limitations that are addressed above. Instant Claims Reference U.S. Patent No. 12,472,333 9. A surgical device, comprising: a cylindrical catheter that extends along a longitudinal axis; an elongated first ring which is in contact with and movable along the cylindrical catheter; and a surgical tool directly or indirectly attached to the elongated first ring 1. A surgical device, comprising: a cylindrical catheter that extends along a longitudinal axis; a first ring which is in contact with and movable along the cylindrical catheter; a second ring which is movable around the cylindrical catheter; and a surgical tool directly or indirectly attached to the first ring, wherein, the first and second rings are configured so that movement of the second ring in a first direction along the longitudinal axis causes a corresponding movement of the first ring in the same direction along the longitudinal axis, and the cylindrical catheter can be moved through and independent of the first ring. Claim 9 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 12,472,333. As shown in the mapping below, claim 1 of the reference patent includes all the limitations of claim 9 of the instant application, while also reciting further limitations, i.e. a second ring, elongated first ring. The term, elongated first ring, is an obvious variant of the patented claims and does not critically or functionally differentiate the capability or function of the surgical device. Every limitation in the application under examination claims is recited in the conflicting reference patent claims and the differences between the claims are highlighted below by bolding all limitations that differ, italicizing additional limitations and underlining limitations that are addressed above. Instant Claims Reference U.S. Patent No. 11,628,283 9. A surgical device, comprising: a cylindrical catheter that extends along a longitudinal axis; an elongated first ring which is in contact with and movable along the cylindrical catheter; and a surgical tool directly or indirectly attached to the elongated first ring 1. A surgical device, comprising: a cylindrical catheter that extends along a longitudinal axis; a first ring which is in contact with and movable along the cylindrical catheter; a second, separate, ring which is in contact with and movable along the cylindrical catheter; and a surgical tool directly or indirectly attached to the first ring, wherein, the first and second rings are configured so that movement of the second ring in a first direction along the longitudinal axis causes a corresponding movement of the first ring in the same direction along the longitudinal axis, and the cylindrical catheter can be moved through and independent of the first ring. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 9 is/are rejected under 35 U.S.C. 102(1) as being anticipated by Valley et al. (US 5,766,151, “Valley”). Regarding claim 9, Valley discloses a surgical device including a cylindrical catheter (920; Fig. 30A) that extends along a longitudinal axis. An elongated first ring (900) is in contact with and movable along the cylindrical catheter (C40; L59-61). A surgical tool (906; suture) is directly or indirectly attached to the elongated first ring. Claim(s) 9 is/are rejected under 35 U.S.C. 102(1) as being anticipated by Gellman (US 2006/0212022A1, “Gellman”). Regarding claim 9, Gellman discloses a surgical device including a cylindrical catheter (12; Fig. 4) that extends along a longitudinal axis. An elongated first ring (10) is in contact with and movable along the cylindrical catheter [0027]. A surgical tool (14; balloon) is directly or indirectly attached to the elongated first ring. Response to Arguments Applicant’s arguments with respect to claim(s) 9 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Gerrans et al. (US 2016/0067465A1) discloses a cylindrical catheter along which an elongated ring may slide. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOCELIN C TANNER whose telephone number is (571)270-5202. The examiner can normally be reached M-F 8am-4pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jackie Ho can be reached at (571)272-4696. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOCELIN C TANNER/ Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Jan 18, 2025
Application Filed
May 26, 2026
Non-Final Rejection mailed — §102, §DOUBLEPATENT
Aug 25, 2026
Examiner Interview (Telephonic)
Aug 25, 2026
Response Filed
Aug 27, 2026
Examiner Interview Summary
Oct 14, 2026
Final Rejection mailed — §102, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778777
VASCULAR ACCESS DEVICES AND METHODS FOR LOWER LIMB INTERVENTIONS
1y 10m to grant Granted Nov 03, 2026
Patent 12773346
INCISION GUIDE TOOL FOR OCULAR DEVICE IMPLANTATION AND METHODS OF USE
2y 0m to grant Granted Oct 27, 2026
Patent 12773316
LOCATION INDICATION SYSTEM FOR IMPLANT-DELIVERY TOOL
1y 9m to grant Granted Oct 27, 2026
Patent 12765917
SYSTEMS AND METHODS FOR CERVICAL RIPENING
2y 6m to grant Granted Oct 20, 2026
Patent 12758241
Tubular Thrombectomy Devices
3y 5m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
72%
Grant Probability
99%
With Interview (+34.8%)
3y 2m (~1y 4m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1071 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month